Diabetes

18 March 2010

Two diabetes drugs fail to help high-risk patients

The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.

0

This article has not necessarily been edited by Health24.

ATLANTA (Reuters) - The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.

The 9,306-patient study tested Starlix, known chemically as nateglinide, and the big-selling Novartis blood pressure medicine Diovan.Diovan, known chemically as valsartan, reduced progression to diabetes by 14 percent compared to a placebo but failed to reduce the risk of serious heart problems, such as heart attack and stroke, according to researchers who presented the data at the American College of Cardiology scientific meeting in Atlanta.

The failure of Starlix to provide benefit to these patients and lack of heart impact by Diovan came as a surprise to researchers."Most experts believed that nateglinide would prevent diabetes and that valsartan would reduce cardiovascular events in this population," said Dr. Robert Califf, the study's lead investigator."Interestingly, with respect to nateglinide, we found the opposite," Cardiff said.Starlix works by minimizing spikes in blood sugar after meals by stimulating the pancreas to produce more insulin, leading researchers to believe it might slow progression to diabetes by restoring a more normal insulin response.

In addition to the drugs or placebo, all patients in the Novartis-sponsored study were required to take part in a lifestyle program with a goal of maintaining a 5 percent weight loss, increasing physical activity to an average of 30 minutes five days a week, and follow a low-fat diet.Patients were followed for an average of five years for development of diabetes and 6.5 years for heart disease.

Impact on heart risk was measured by a combination of death from cardiovascular causes, nonfatal heart attacks, nonfatal stroke, hospitalization for heart failure, unstable chest pain and the need for artery-clearing procedures.Researchers speculated that the negative results seen with the two drugs may have been related to success of the diet and exercise program in reducing progression to diabetes and heart risk.

They also said other medicines many patients were taking, such as cholesterol-lowering drugs, may have lowered the overall risk.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules